Physician profile
Albert U Ma
NPI 1275596496
$8,150.80
in general payments reported to CMS, 2019-2025
24 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $894 · 2021: $1,854 · 2022: $1,047 · 2023: $642 · 2024: $573 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.57 |
| Education | $185.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,496.45 | 2019-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $1,274.67 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $1,132.04 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $1,054.04 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $849.48 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $444.96 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $426.73 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Tris Pharma INC | $345.33 | 2019-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $320.83 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.16 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $119.91 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $74.20 | 2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $69.24 | 2021-2024 | |
| Nevro Corp. | $64.48 | 2023 | Senza |
| Neurocrine Biosciences, INC. | $62.44 | 2023 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.13 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $47.69 | 2022-2024 | |
| Globus Medical, INC. | $40.66 | 2025 | Senza |
| Shire North American Group INC | $30.36 | 2019 | |
| Indivior INC. | $22.14 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.55 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.64 | 2019 | |
| Corium, LLC | $13.33 | 2022 | |
| Axsome Therapeutics, INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.